Radiolabeled peptides in diagnosis and tumor imaging: Clinical overview

Seminars in Nuclear Medicine

Volumn 32, Issue 2, 2002, Pages 79-83

  Warner, Richard R P ^a,b,c,d   O'Dorisio, Thomas M ^a,b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; DOPA; OCTREOTIDE; PENTETREOTIDE; PEPTIDE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; SUCCIMER TC 99M; VAPREOTIDE;

HUMAN; IMAGING; ISOTOPE LABELING; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; RECEPTOR AFFINITY; REVIEW; SCINTIGRAPHY; THYROID MEDULLARY CARCINOMA; TUMOR; TUMOR DIAGNOSIS; UNITED STATES;

EID: 0036223553     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2002.31020     Document Type: Article

References (32)

1. Radio-labeled receptor-binding peptides: A new class of radiopharmaceuticals
2. Somatostatiny analogs in oncology: A look to the future
3. Somatostatin analogs for cancer treatment and diagnosis: An overview
4. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumors
5. Somatostatin receptors
6. 111In-octreotide scintigraphy in pituitary adenomas
7. 111In-DTPA-D-Phe]-Octreotide scintigraphy in functioning and nonfunctioning pituitary adenomas
8. Peptide receptor imaging and therapy
9. Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization
10. Specificity of somatostatin receptor scintigraphy: A prospective study and effects of false-positive localization on management in patients with gastrinoma
11. Editorial: Somatostatin receptor-based scintigraphy and anti-tumor treatment - An expanding vista?
12. Somatostatin receptor scintigraphy with [11lIn-DTPA-D-Phel]-and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1,000 patients
13. The utility of a somatostatin type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules
14. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy
15. 99mTc-labeled vasoactive intestinal peptides analog for rapid localization of tumors in humans
16. Carcinoid and pancreatic endocrine tumors: Recent advances in molecular pathogenesis, localization and treatment
17. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors
18. Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: A prospective study
19. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies
20. 18F dopa PET for detection of gastrointestinal carcinoid tumors
21. Indium-111-DTPA-octreotide scintigraphy modulation by treatment with unlabeled somatostatin analog in small-cell lung cancer
22. Somatostatin receptor scintigraphy in patients with carcinoid tumors: Comparison between radioligand uptake and tumor markers
23. Somatostatin, its receptors and analogs, in lung cancer
24. Gene transfer strategies for improving radiolabeled peptide imaging and therapy
25. Uses of somatostatin receptor scintigraphy to image extra-hepatic metastases of neuroendocrine tumors
26. 125-TYR(3)-octreotide and a hand-held gamma-detecting probe
27. Intraoperative localization of gut endocrine tumors with radiolabeled somatostatin analogs and a gamma-detecting probe
28. Intraoperative use of gamma-detecting probes for localized neuroendocrine tumors
29. 125I-lanreotide in women with primary breast cancer
30. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors
31. Receptor targeting for tumor localisation and therapy with radiopeptides
32. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors